E-Z-PASTE- barium sulfate cream E-Z-EM Canada Inc

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

NDC 32909-770-01 E-Z-PASTE[®] BARIUM SULFATE ESOPHAGEAL CREAM (60% w/w)

DESCRIPTION

E-Z-PASTE[®] Barium Sulfate Esophageal Cream (60% w/w) is a barium sulfate cream for oral administration. Each 100 g contains 60 g barium sulfate. Barium sulfate, due to its high molecular density is opaque to x-rays and, therefore, acts as a positive contrast agent for radiographic studies. The active ingredient is barium sulfate and its structural formula is BaSO₄. Barium sulfate occurs as a fine, white, odorless, tasteless, bulky powder which is free from grittiness. Its aqueous suspensions are neutral to litmus. It is practically insoluble in water, solutions of acids and alkalies, and organic solvents.

Inactive Ingredients: carboxymethylcellulose sodium, citric acid, ethyl vanillin, glycerin, methylparaben, propylparaben, purified water, saccharin sodium, simethicone emulsion, sodium citrate, and sorbitol solution.

CLINICAL PHARMACOLOGY

Barium sulfate, due to its high molecular density is opaque to x-rays and, therefore, acts as a positive contrast agent for radiographic studies. Barium sulfate is biologically inert and therefore, is not absorbed or metabolized by the body, and is eliminated unchanged from the body.

INDICATIONS AND USAGE

For use in single contrast radiography of the esophagus, pharynx, hypopharynx and for cardiac series.

CONTRAINDICATIONS

This product should not be used in patients with known gastric or intestinal perforation or hypersensitivity to barium sulfate products.

WARNINGS

Rarely, severe allergic reactions of an anaphylactoid nature, have been reported following administration of barium sulfate contrast agents. Appropriately trained

personnel and facilities should be available for emergency treatment of severe reactions and should remain available for at least 30 to 60 minutes following administration, since delayed reactions can occur.

PRECAUTIONS

General

Diagnostic procedures which involve the use of radiopaque contrast agents should be carried out under the direction of personnel with the requisite training and with a thorough knowledge of the particular procedure to be performed. A history of bronchial asthma, atopy, as evidenced by hay fever and eczema, or a previous reaction to a contrast agent, warrant special attention. Caution should be exercised with the use of radiopaque media in severely debilitated patients and in those with marked hypertension or advanced cardiac disease.

Caution should be used during the administration of this product to patients with a history of food aspiration or to patients in whom integrity of the swallowing mechanism is unknown. If this product is aspirated into the larynx, further administration should be discontinued immediately.

After any barium study of the GI tract, it is important to rehydrate the patient as quickly as possible to prevent impaction of the bowel by barium sulfate. To prevent barium sulfate impaction in the bowel, the use of mild laxatives such as milk of magnesia or lactulose, following completion of the examination may also be required. These mild laxatives are recommended on a routine basis and in patients with a history of constipation unless contraindicated.

Use with caution with complete or nearly complete esophageal or gastric obstruction.

Information for Patients

Before administration of this product patients should be instructed to:

- 1. Inform their physician if they are pregnant.
- 2. Inform their physician if they are allergic to any drugs or food, or if they have had any prior reactions to barium sulfate products or other contrast agents used in x-ray procedures (see **PRECAUTIONS-General**).
- 3. Inform their physician about any other medications they are currently taking.

Drug Interactions

The presence of barium sulfate formulations in the GI tract may alter the absorption of therapeutic agents taken concomitantly. In order to minimize any potential change in absorption, the separate administration of barium sulfate from that of other agents should be considered.

Usage in Pregnancy

Radiation is known to cause harm to the unborn fetus exposed in utero. Therefore, radiographic procedures should only be used when, in the judgement of the physician, its use is deemed essential to the welfare of the pregnant patient.

Nursing Mothers

Barium sulfate products may be used during lactation.

ADVERSE REACTIONS

Adverse reactions, such as nausea, vomiting, diarrhea and abdominal cramping, accompanying the use of barium sulfate formulations are infrequent and usually mild. Severe reactions (approximately 1 in 1,000,000) and fatalities (approximately 1 in 10,000,000) have occurred. Procedural complications are rare, but may include aspiration pneumonitis, barium sulfate impaction, granuloma formation, intravasation, embolization and peritonitis following intestinal perforation, vasovagal and syncopal episodes, and fatalities. It is of the utmost importance to be completely prepared to treat any such occurrence.

ALLERGIC REACTIONS

Due to the increased likelihood of allergic reactions in atopic patients, it is important that a complete history of known and suspected allergies as well as allergic-like symptoms, e.g., rhinitis, bron-chial asthma, eczema and urticaria, must be obtained prior to any medical procedure utilizing these products. A mild allergic reaction would most likely include generalized pruritus, erythema or urticaria (approximately 1 in 250,000). Such reactions will generally respond to an antihistamine such as 50 mg of diphenhydramine or its equivalent. In the rarer, more serious reactions (approximately 1 in 1,000,000) laryngeal edema, bronchospasm or hypotension could develop. Severe reactions which may require emergency measures are often characterized by peripheral vasodilation, hypotension, reflex tachycardia, dyspnea, agitation, confusion and cyanosis progressing to unconsciousness. Treatment should be initiated immediately with 0.3 to 0.5 mL of 1:1000 epinephrine subcutaneously. If bronchospasm predominates, 0.25 to 0.50 grams of intravenous aminophylline should be given slowly. Appropriate vasopressors might be required. Adrenocorticosteroids, even if given intravenously, exert no significant effect on the acute allergic reactions for a few hours. The administration of these agents should not be regarded as emergency measures for the treatment of allergic reactions.

Apprehensive patients may develop weakness, pallor, tinnitus, diaphoresis and bradycardia following the administration of any diagnostic agent. Such reactions are usually non-allergic in nature and are best treated by having the patient lie flat for an additional 10 to 30 minutes under observation.

OVERDOSAGE

On rare occasions following repeated administration, severe stomach cramps, nausea, vomiting, diarrhea or constipation may occur. These are transitory in nature and are not considered serious. Symptoms may be treated according to currently accepted standards of medical care.

DOSAGE AND ADMINISTRATION

Usual dose is one to four teaspoons as required.

Storage

Store product at USP Controlled Room Temperature, 20 to 25°C (68 to 77°F). Protect from freezing.

HOW SUPPLIED

E-Z-PASTE[®] is supplied in the following quantity: 454 g Tube, Cat. No. 770; NDC 32909-770-01

Manufactured by E-Z-EM Canada Inc. for E-Z-EM, Inc. a subsidiary of Bracco Diagnostics Inc. Monroe Township, NJ 08831 Tel: 1-516-333-8230 1-800 544-4624


rev. 10/17 CL80E01 TX1887

E-Z-Paste - Barium Sulfate Esophageal Cream

NDC: 32909-770-01

CL80E02

rev. 01/2023



E-Z-Paste - Carton



E-Z-PASTE barium sulfate cream			
Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	ltem Code (Source)	NDC:32909-770
Route of Administration	ORAL		

Active Ingredi		-					
Ingredient Name					Basis of Strength		Strength
BARIUM SULFATE	(UNII: 25BB7EI	KE2E) (BARIUM SULFATE - UNII:25BB7EKE		37EKE2E)	E) BARIUM SULFATE		.6 g in 1 g
Inactive Ingre	dianta						
mactive mgre	ulents	In a vertice at No.				C 1	
						51	rength
DIMETHICONE 350		ODIUM (UNII: K679OBS	311)				
DIMETHICONE 330	-	•					
ETHYL VANILLIN (U							
GLYCERIN (UNII: PD		([])					
METHYLPARABEN		I9T)					
PROPYLPARABEN							
SACCHARIN SODIU							
SILICON DIOXIDE							
SORBITOL (UNII: 50	-						
		E (UNII: B22547B95K)					
WATER (UNII: 059Q							
ANHYDROUS CITR	IC ACID (UNII:	XF417D3PSL)					
Product Chara	acteristics						
Color		WHITE	Score				
Shape			Size	Size			
Flavor		VANILLA	Imprint	Imprint Code			
Contains							
Packaging							
# Item Code	Pa	ckage Description		Marketin Dat			ing End ate
1 NDC:32909-770- 01	1 in 1 BOX	1 in 1 BOX					
1	454 g in 1 TUBE; Type 0: Not a Combination Product						
Marketing	Informat	ion					
Marketing Category		Application Number or Monograph Citation			ing Start ate		ting End ate
Unapproved drug other				06/01/1974	1		

Labeler - E-Z-EM Canada Inc (204211163)

Registrant - E-Z-EM, INC. (002041226)

Establishment						
Name	Address	ID/FEI	Business Operations			
E-Z-EM Canada Inc		204211163	ANALYSIS(32909-770), MANUFACTURE(32909-770), LABEL(32909-770), PACK(32909-770)			

Revised: 7/2023

E-Z-EM Canada Inc